Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes
- 276 Downloads
Programmed cell death 1 (PD-1) is a co-inhibitory molecule expressed on effector T cells and is involved in regulation of immune checkpoints. One of the known ligands of PD-1 protein is programmed cell death ligand 1 (PDL-1), which is expressed in many tumor cells. Activation of PD-1/PDL-1 axis results in suppression of anti-tumor immune checkpoints. Pembrolizumab is an immunoglobulin G4 monoclonal antibody targeting PD-1 molecule that increases immune response and induces anti-tumor activity. It has been approved for treating metastatic melanoma and is currently on clinical investigation for several other tumors including non-small cell lung cancer. On the other hand, PD-1 or PDL-1 blockade induced type 1 diabetes mellitus (T1DM) in non-obese prediabetic mice regardless of age . In humans, few case reports of anti-PD-1 therapy induced T1DM have been reported including one case of fulminant T1DM [2, 3]. Here, we described a case of new-onset fulminant T1DM after...
KeywordsChronic Pancreatitis Glimepiride Diabetic Ketoacidosis Immune Checkpoint Subclinical Hyperthyroidism
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (IRB No. 1508-041-694) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.
Human and animal rights
This article does not contain any studies with animals performed by any of the authors.
Informed consent was obtained from all individual participants included in the study.
- 4.Imagawa A, Hanafusa T, Awata T et al (2012) Report of the committee of the Japan diabetes society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012). J Diabetes Investig 3(6):536–539. doi: 10.1111/jdi.12024 CrossRefPubMedPubMedCentralGoogle Scholar